Gilead Sciences, Inc. and Gritstone Oncology, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a curative treatment for HIV infection.   The companies aim to develop an HIV-specific therapeutic vaccine using Gritstone’s prime-boost vaccine platform, comprised of self-amplif...